Loading
companiesCompany
BeOne Medicines (formerly BeiGene)
BeOne Medicines makes Brukinsa, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab.
Also called: BeiGeneBeiGene USAInc.BeOneBeOne (BeiGene)GW Pharmaceuticals Ltd
· 1 more · Fewer names
GW Pharmaceuticals
Overview
BeOne Medicines, formerly BeiGene, based in Basel and Beijing and listed as ONC, makes Brukinsa, or zanubrutinib, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab. Its pipeline includes sonrotoclax, a BCL-2 inhibitor, and the BTK degrader BGB-16673, with the RATIONALE-302 trial linked, and John Oyler and Jie Wang among the people connected. OnCo links it to chronic lymphocytic leukaemia, mantle cell and follicular lymphoma, gastric and nasopharyngeal cancer, and to bottlenecks on acquired resistance, regulatory divergence and unrepresentative trials, which its China-to-global model bears on. Whether a BTK degrader can overcome resistance to its own BTK inhibitor is the open question. Zanubrutinib and zanidatamab have their own pages.
Headquarters
Basel / Beijing, CH
Scorecard
All companies#19of 1244 companies, score 105
- approved products +24
- phase 3 +9
- targets +8
- modalities +8
- regions +6
- 24-month regulatory events +20
- registry trials +30
4 approved, 3 in phase 3, 0 earlier, 4 targets, 923 registry studies. Formula on the scorecards page.
Financial snapshot, FY2024
- Total revenue
- $3.8bn
- R&D spend
- $2.0bn
- Cash
- $2.6bn
Brukinsa $2.6bn
Essentially all revenue is oncology. Cash is cash, cash equivalents and restricted cash. BeiGene (now BeOne Medicines) Form 10-K, FY2024 (SEC EDGAR)
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2021-01-11 | BeOne Medicines (formerly BeiGene) to Novartis Tislelizumab, anti-PD-1 antibody | Licence | $650m | up to $2.2bn | source |
Type
Biotech · ONC
Stage
Public
Website
ApprovedBiparatopic bispecific antibody (HER2)
Zanidatamab · Ziihera
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
BGB-43395 is an experimental small-molecule drug from BeOne Medicines in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
ApprovedOral PARP inhibitor
Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.
Phase 3Small-molecule BTK degrader (CDAC)
Instead of blocking BTK, this pill destroys it, so it works even when the enzyme has mutated to escape every inhibitor.
ApprovedSmall-molecule BCL-2 inhibitor (second generation)
Sonrotoclax · Beqalzi
Sonrotoclax is a more potent, shorter-acting successor to venetoclax. It was approved for mantle cell lymphoma in May 2026 and is in late-stage trials with zanubrutinib for CLL.
ApprovedMonoclonal antibody (anti-PD-1)
Tislelizumab · Tevimbra
A Chinese-developed PD-1 blocker, engineered to avoid a side-channel that may blunt other PD-1 drugs, now approved in the US and EU for oesophageal and stomach cancer.
ApprovedSmall-molecule covalent BTK inhibitor (second generation)
Zanubrutinib · Brukinsa
Zanubrutinib is the only BTK blocker to beat ibrutinib on both efficacy and safety in a head-to-head trial. It is now the most prescribed BTK inhibitor in CLL.
Jie Wang
Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences
Lung cancerImmunotherapyTargeted therapy
Led the RATIONALE trials of tislelizumab in lung cancer and many other Chinese registrational NSCLC studies.
John Oyler
Co-founder, Chairman and CEO, BeOne Medicines (formerly BeiGene)
Biotech leadershipGlobal clinical developmentOncology commercialisation
John Oyler co-founded BeiGene in Beijing in 2010 and built it into the first China-born biotech to run global trials, win FDA approvals and out-sell Western rivals with zanubrutinib.
Similar pages
- TechnologyBCL-2 inhibitors
Shares Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma, A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia, A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac, A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers..
- CancerRelapsed or refractory chronic lymphocytic leukaemia
Shares A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors, A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL).
- TargetBTK (Bruton tyrosine kinase)
Shares ALPINE, CaDAnCe-304, BGB-16673, CELESTIAL-TNCLL.
- TreatmentObinutuzumab
Shares A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies, A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors, A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom, A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL).
- CancerChronic lymphocytic leukaemia, first treatment
Shares A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia, A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia, CaDAnCe-304, CELESTIAL-TNCLL.
- TreatmentPirtobrutinib
Shares A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, CaDAnCe-304, Waldenström macroglobulinaemia, Acquired resistance to every therapy.
- TreatmentBendamustine
Shares A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors, A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors, A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl, Waldenström macroglobulinaemia.
- IdeaBTK degraders to pre-empt resistance in frontline CLL
Shares CaDAnCe-304, BGB-16673, Sonrotoclax, Acquired resistance to every therapy.
cancers
fronts
drugs
Phase 3Small-molecule BTK degrader (CDAC)
Phase 3small molecule (structure undisclosed or not yet in PubChem)
ApprovedOral PARP inhibitor
ApprovedSmall-molecule BCL-2 inhibitor (second generation)
Sonrotoclax · Beqalzi
ApprovedMonoclonal antibody (anti-PD-1)
Tislelizumab · Tevimbra
ApprovedBiparatopic bispecific antibody (HER2)
Zanidatamab · Ziihera
ApprovedSmall-molecule covalent BTK inhibitor (second generation)
Zanubrutinib · Brukinsa
institutions
trials
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic SolA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus DaratA Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCA Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus A Study of BGB-11417 in Participants With Myeloid MalignanciesA Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLA Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsA Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerA Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesA Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaA Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaA Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in ParticipantsA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/RefracA Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated MantlA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor BurdenAdjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal CancerALPINEASPEN (Waldenström macroglobulinaemia)BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseCaDAnCe-304CELESTIAL-TNCLLComparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)HERIZON-BTC-01HERIZON-GEA-01Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerMRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLCNeoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal CancerRATIONALE-302RATIONALE-306Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaStudy of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell LymphomaStudy of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsTislelizumab in People With Colorectal CancerTrametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader